Singapore's premier podcast on the biotech ecosystem.
The show notes and transcripts can be found on nucleatesingapore.substack.com. Subscribe and follow us to keep your finger on the pulse of Singapore’s biotech ecosystem.
For feedback and suggestions, feel free to reach out to the team at singapore@nucleate.org
Bridging Local Startups to Global Markets with Elia Stupka of Angelini Ventures - Part 2
In part two of this episode, Dr. Elia Stupka explains why Angelini Ventures established a Singapore office: high-conviction “boots on the ground” in a rapidly transforming Asia, Singapore’s role as a multilingual, legally strong APAC base, and a maturing local ecosystem with A*STAR science and clinical excellence. He describes EspressoLab, created with Enterprise Singapore as a hands-on, transparent program that helps earlier-stage startups avoid common Series A mistakes, match with global advisors via a bespoke “barista” model, and use of an AI augmented diligence. Stupka outlines Singapore biotech challenges, especially the lack of industry-experienced CMOs and limited talent pool, and suggests Singapore should combine local and global innovation as a hub. He discusses China’s surge in licensing deals and the likely rise of global Chinese pharmas, argues healthcare will follow “faster, better, cheaper” global dynamics with regulators racing toward higher standards, and shares founder traits he values, plus Angelini Ventures’ focus across biotech, medtech, and digital health.
Host: Shamieraah Jamal
Editor: Dillon Chew
Podcast Team: Chi Dam, Alefiya Dohadwala, Chelsia Goh
19 Oct 2026
Bridging Local Startups to Global Markets with Elia Stupka of Angelini Ventures - Part 1
In this episode, Dr. Elia Stupka, Managing Director of Angelini Ventures, traces his path from early computational biology to venture capital. He describes pioneering days on the Human Genome Project in Cambridge, the startup-like pace of building genome annotation tools and infrastructure, and helping launch Singapore’s fugu genome project with Sydney Brenner. He also contrasts academia’s grant-and-paper incentives with industry’s emphasis on deep validation, then explains how open innovation work at Boehringer Ingelheim and advising startups led him into investing. He outlines Angelini Ventures’ global, evergreen structure, its approach to evaluating biotech/medtech/digital health, his high-risk/high-reward style, and the hands-on post-investment work that drives outcomes, including why the firm built a presence in Singapore and Asia.
Host: Shamieraah Jamal
Editor: Dillon Chew
Podcast Team: Chi Dam, Alefiya Dohadwala, Chelsia Goh
19 Sept 2026
Reprogramming cells with AI for improved biologics manufacturing with Jie Sun of ChemT Biotech
Jie Sun, Co-founder and CEO of ChemT Biotechnology, joins the show to discuss how artificial intelligence, virtual cell models, and small-molecule interventions could reshape biologics manufacturing. Drawing on a career spanning healthcare consulting, pharmaceutical project management, regulated healthcare AI, and entrepreneurship, Jie shares how her experience across Southeast Asia and the United States shaped her approach to identifying valuable problems and building globally relevant companies.
In this episode, Jie explains why ChemT Biotechnology chose biomanufacturing as the focus for its virtual cell platform. Rather than applying AI primarily to develop drugs for patients, the company designs what Jie calls “cellular drugs,” small molecules intended to modulate the behaviour of manufacturing cells. The approach combines gene-target identification, prediction of cell-state and phenotypic changes, and AI-assisted generation and filtering of small-molecule structures.
Jie also discusses why wet-lab validation remains the ultimate test for AI-driven biotechnology. She argues that AI models alone are becoming increasingly commoditised, while defensibility comes from proprietary data, deep manufacturing context, and the ability to translate technology into a product that solves a customer’s problem faster, more cheaply, or more effectively.
Host: Tan Mei Jia
Editors: Dillon Chew, Chi Dam
01:25 About Jie Sun and her background
08:05 First startup experience
15:25 The ChemT Biotech Story
18:10 Role of AI in ChemT
23:25 More on their product
25:36 Funding and expansion
32:33 On Female founders
37:44 Advice to aspiring founders
Reach and audience
Public platform figures. Ratings count people who left a rating, not total listeners.
Apple Podcasts (US)
5.0 / 5
1 ratings
Spotify
5.0 / 5
8 ratings
Podcast Authority Score: 39 / 100
A composite of feed quality, social presence, YouTube performance and engagement. Read the methodology.
Quality
54
Social presence
0
YouTube
0
Engagement
60
Contact Nucleate Singapore Pulse
Guest appearances
Books guests
Based on episode analysis; this does not confirm that the show is currently accepting guests.
Host of Nucleate Singapore Pulse?
Claim your podcast to manage its listing and keep your show details accurate.
Pod Engine is an independent podcast discovery and analytics service and is not affiliated with or endorsed by this podcast. Artwork and show content belong to their owners. Full legal notice.
Explore this show Podcast research with Pod Engine
